This company is no longer active
InDex Pharmaceuticals Holding Performance dei guadagni passati
Il passato criteri di controllo 0/6
InDex Pharmaceuticals Holding has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 89.5% per year.
Informazioni chiave
2.7%
Tasso di crescita degli utili
53.7%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 30.5% |
| Tasso di crescita dei ricavi | 89.5% |
| Rendimento del capitale proprio | -23.9% |
| Margine netto | -52.1% |
| Prossimo aggiornamento sui guadagni | 20 Aug 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Ripartizione dei ricavi e delle spese
Come InDex Pharmaceuticals Holding guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 24 | 108 | -56 | 171 | 0 |
| 31 Dec 23 | 98 | -95 | 188 | 0 |
| 30 Sep 23 | 98 | -46 | 143 | 0 |
| 30 Jun 23 | 98 | -12 | 134 | 0 |
| 31 Mar 23 | 1 | -123 | 156 | 0 |
| 31 Dec 22 | 1 | -100 | 140 | 0 |
| 30 Sep 22 | -2 | -67 | 123 | 0 |
| 30 Jun 22 | -2 | -92 | 127 | 0 |
| 31 Mar 22 | 0 | -113 | 117 | 0 |
| 31 Dec 21 | 0 | -103 | 100 | 0 |
| 30 Sep 21 | 3 | -90 | 86 | 0 |
| 30 Jun 21 | 3 | -70 | 59 | 0 |
| 31 Mar 21 | 0 | -43 | 35 | 0 |
| 31 Dec 20 | 0 | -57 | 41 | 0 |
| 30 Sep 20 | 0 | -73 | 53 | 0 |
| 30 Jun 20 | 0 | -92 | 73 | 0 |
| 31 Mar 20 | 0 | -95 | 80 | 0 |
| 31 Dec 19 | 0 | -88 | 83 | 0 |
| 30 Sep 19 | 0 | -84 | 83 | 0 |
| 30 Jun 19 | 0 | -72 | 71 | 0 |
| 31 Mar 19 | 0 | -81 | 80 | 0 |
| 31 Dec 18 | 1 | -82 | 81 | 0 |
| 30 Sep 18 | 0 | -82 | 82 | 0 |
| 30 Jun 18 | 0 | -80 | 80 | 0 |
| 31 Mar 18 | 0 | -69 | 69 | 0 |
| 31 Dec 17 | 0 | -73 | 63 | 0 |
| 30 Sep 17 | 0 | -67 | 54 | 0 |
| 30 Jun 17 | 0 | -61 | 48 | 0 |
| 31 Mar 17 | 0 | -56 | 41 | 0 |
| 31 Dec 16 | 0 | -41 | 34 | 0 |
| 30 Sep 16 | 0 | -31 | 28 | 0 |
| 30 Jun 16 | 0 | -31 | 29 | 0 |
| 31 Mar 16 | 0 | -29 | 28 | 0 |
| 31 Dec 15 | 0 | -30 | 28 | 0 |
| 30 Sep 15 | 0 | -33 | 30 | 0 |
| 30 Jun 15 | 0 | -36 | 32 | 0 |
| 31 Mar 15 | 23 | -25 | 42 | 0 |
| 31 Dec 14 | 45 | -15 | 52 | 0 |
| 31 Dec 13 | 1 | -68 | 62 | 0 |
Guadagni di qualità: INDEX is currently unprofitable.
Margine di profitto in crescita: INDEX is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: INDEX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.
Accelerare la crescita: Unable to compare INDEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: INDEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.1%).
Rendimento del capitale proprio
ROE elevato: INDEX has a negative Return on Equity (-23.93%), as it is currently unprofitable.